CoQ10 in Patients with Nonalcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is the most common cause of chronic liver injury.  After 4 weeks of CoQ10 supplementation, waist circumference and serum AST concentrations were significantly decreased as compared to the placebo-treated group.  The study showed a potential for CoQ10 therapy in improving serveral anthropometric and biochemical variables in non-alcoholic fatty liver disease.  Longer studies with higher doses of CoQ10 are required to further evaluate this potential benefit.

Here is the link to the entire article:

Oral Coenzyme Q10 Supplementation Improves Various Anthropometric and Biochemical Variables in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

God bless you and to your good health!

Joyce Gibb MS, CRNP
Ask The Pharmacist Group, LLC

Contact Us

To place an order or ask a question: 800-609-6633

From Canada (or outside the US):

To schedule an assessment:

To phone the show:
M-F Radio show: 1-800-281-8255

Sat Radio show: 1-800-320-8255


Join our newsletter today and receive a 10% OFF coupon!